PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
PepGen Inc. (PEPG)
Company Research
Source: Business Wire
– FREEDOM-DM1 data from 5 and 10 mg/kg cohorts in patients with DM1 expected in the first quarter of 2025 –– Study designs of CONNECT program optimized based on encouraging results from early cohort –– Strengthened leadership team with addition of Paul Streck, MD, MBA, as head of R&D – BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended September 30, 2024.“We are pleased with the progress we have made across our pipeline and organization during the third quarter, as we continued to advance our lead clinical programs and strengthened our leadership team with the addition of Paul Streck to head our research and clinical development efforts. Paul has already made a positive impact on our organization and our
Show less
Read more
Impact Snapshot
Event Time:
PEPG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PEPG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PEPG alerts
High impacting PepGen Inc. news events
Weekly update
A roundup of the hottest topics
PEPG
News
- PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development [Yahoo! Finance]Yahoo! Finance
- PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical DevelopmentBusiness Wire
- PepGen Inc. (NASDAQ: PEPG) had its price target lowered by analysts at Bank of America Co. from $10.00 to $6.00. They now have a "neutral" rating on the stock.MarketBeat
- PepGen Inc. (NASDAQ: PEPG) had its price target lowered by analysts at Wedbush from $19.00 to $12.00. They now have an "outperform" rating on the stock.MarketBeat
- PepGen Inc. (NASDAQ: PEPG) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.MarketBeat
PEPG
Earnings
- 8/8/24 - Miss
PEPG
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- PEPG's page on the SEC website